Please login to the form below

Not currently logged in
Email:
Password:

daclatasvir

This page shows the latest daclatasvir news and features for those working in and with pharma, biotech and healthcare.

Gilead gets OK for three-in-one hep C therapy in US

Gilead gets OK for three-in-one hep C therapy in US

Other NS5A inhibitors on the market for HCV include Gilead's ledipasvir, Bristol-Myers Squibb's daclatasvir, AbbVie's dasabuvir and Merck &Co's elbasvir.

Latest news

More from news
Approximately 6 fully matching, plus 25 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcircle

We're Healthcircle – an award-winning healthcare advertising and creative communications agency, offering a holistic approach to brand health. With a...

Latest intelligence

How do companies prepare for reimbursement?
Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
EHR clinical trials
Integrating electronic health records into clinical trials
How organisations are working to realise the research potential of EHRs...
Mike Elliott Gilead
Keeping up the fight against HIV and using the lessons to tackle other threats
Danny Buckland interviews Gilead’s Mike Elliott...

Infographics